Millipore hopes its $23m (€18m) swoop for Guava Technologies will draw attention away from the underperformance of its bioprocess division, revenue from which fell 6 per cent in Q4 to $214m (€165m) and 2 per cent for 2008 overall.
The lacklustre performance of Millipore’s bioprocess division has continued into the second quarter of the year with revenues reaching $229.8m (€147m) up just one per cent on the comparable 2007 quarter.
Danish diabetes care specialist Novo Nordisk has expanded an
agreement with biotech supplier Millipore, granting exclusive,
long-term distribution rights to the company's insulin
products for cell culture applications.
One-off costs related to last year's acquisition of Serologicals
and a continuing manufacturing consolidation strategy were largely
responsible for sharp falls in Millipore's pre-tax and net profits
for the first quarter...
US-based biopharmaceutical product providers Millipore has met its
revenue and earnings target over the fiscal year, helped by its
Serologicals acquisition in the fourth quarter and a solid
performance by its main business driver:...
Millipore has introduced a new disposable product - NovaSeal - that
ties in with a shift in the bioprocess manufacturing market to the
use of disposable assemblies to shorten production cycles for
Millipore has now made available its GPCRProfiler screening service
that allows more accurate characterisation of lead compounds
enabling pharmaceutical and biotechnology companies to accelerate
their lead optimisation efforts.
In its second acquisition in less than a month, Millipore has
acquired bioprocessing products firm Serologicals for around $1.4bn
(€1bn) in cash, as it tries to boost its growth by expanding in
potentially lucrative market segments.
US filtration giant Millipore is pumping more resources into its
personnel and facilities in Asia, as outsourcing trends and new
laboratory investments in emerging markets such as China and India
are upping demand for its bioscience...
Millipore are to showcase a range of filtration, chromatography,
process monitoring and water purification solutions that are a part
of Millipore's response to an increase in lab investments from
pharma companies, and the emergence...
Millipore, manufacturers of purification systems used in drug
manufacture, posted lower forth-quarter profits, carrying over the
company's previous quarter's performance, after being hit by a
hefty one-off earnings charge.
Millipore has introduced a new 24-well cell culture plate which has
twice the membrane surface area compared with other 24-well plates,
allowing researchers to utilize greater cell mass, which more
closely models cell behaviour.
Manufacturing consolidation and acquisition costs helped reduce net
income as Millipore revealed its 2005 second quarter financial
results. The company has just completed the purchase of two
companies with the intention of increasing...
Millipore continued its shopping trip for new businesses last week
with the purchase of NovAseptic, a Swedish company specialising in
aseptic processing equipment used in the production of
pharmaceutical and biologic drugs.
Millipore has introduced a single-use prefilter for clarification
steps in mammalian cell synthesis that continues the trend towards
increasing use of disposable technologies in the bioprocessing
environment, reports Phil Taylor.
New filtration products for biopharmaceutical development and
production were unveiled at last week's Interphex 2004 exhibition
in New York by two of the main players in the sector - Pall and
Filtration specialist Millipore has reported strong growth in sales
in the fourth quarter of 2003, suggesting that the fortunes of the
biopharmaceutical industry - Millipore's primary customer - may be
on the up.
Millipore has developed a new set of labels for its filter products
that should make it easier for its biopharmaceutical customers to
comply with the obligation to keep accurate batch production
Millipore, which specialises in providing technologies, tools and
services for the discovery, development and production of new
therapeutic drugs, has reported first-quarter 2003 sales of $187
million (€173 million), up 13 per cent...